PATENT CLAIM ANALYSIS

Application Number: 15901601
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-11
Patent Classification: ["514", "313000"]

Abstract:
Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.

Claim (Index 51):
The method of  claim 44 , wherein after 10 years of said administration, the individual is substantially without symptoms of retinal toxicity.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 88.0
- Lexical Diversity: 1.34884
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15446860', '14214307', '15579324', '15814557', '10418421']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7498185601774647
- 35 USC 102 Novelty (BERT): 0.6286027873705134
- Combined Prediction Score: 0.7376969828967697
- Mean Citation Score: 355.44085600000005
- Max Citation Score: 586.63837
- Similarity Product: 514.901536743508

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test